*Klebsiella pneumoniae* has emerged as an important nosocomial pathogen, known as one of the "ESKAPE" pathogens[@b1]. Especially, the prevalence of multi-drug resistant (MDR) *K. pneumoniae* increased dramatically in recent years. This limits efficient clinical treatment tremendously resulting in undesirable treatment outcomes.

To control the spread of drug resistance, the tracking of antimicrobial resistant microorganisms is crucial and has been proposed in the CDC antimicrobial resistance action plan as one of the four core actions[@b2]. Use of multilocus sequence typing (MLST) revealed that the population of MDR *K. pneumoniae* is largely oligoclonal, and some epidemic/endemic clones have been identified. For instance, the extended-spectrum **β**-lactamase (ESBL)-producing *K. pneumoniae* (ESBL-KP) mainly belong to sequence type (ST) 11, ST15, ST101, ST147, and ST336[@b3][@b4][@b5][@b6][@b7], and a specific lineage (ST258) played a major role in dissemination of *Klebsiella pneumoniae* carbapenemases (KPC) worldwide[@b8]. With the rapid development of whole-genome sequencing (WGS), the population structure of MDR pathogens can be dissected at a higher resolution level. This challenges conventional hypotheses on clonal descent of *K. pneumoniae*.

To efficiently control and prevent the dissemination of MDR pathogens in hospital settings, the ability of early detection and the tracking of infected or colonized patients are crucial[@b9]. This is especially a challenge during a prolonged outbreak, as transmissions between patients may be caused by additional reservoirs (e.g. health-care workers and the environment), and/or in case different institutes and/or cities are involved in the outbreak.

In this study, we present our experience in using whole-genome sequencing and further developing an outbreak clone-specific PCR for tracing and controlling a regional and inter-institutional outbreak caused by a ST15 CTX-M-15-KP clone between May 2012 and September 2013 in the northern part of Netherlands.

Materials and Methods
=====================

Setting
-------

The University Medical Center Groningen (UMCG) is a 1,300-bed tertiary-care medical centre in the northern part of Netherlands. The rehabilitation centre is part of the university hospital but located 6-kilometer away from the main centre. Most patients of the rehabilitation center were transferred from the university hospital. If a complication occurred or if additional treatment was required, they were admitted to or visiting the hospital again. Part of the medical staff worked both in the hospital and the rehabilitation center.

Patient tracking and contact tracing
------------------------------------

At the end of August 2012, an increase of ESBL-producing *K. pneumoniae* (ESBL-KP) was observed at the UMCG and the associated rehabilitation centre. To prevent further spread, stringent infection control measures consisting of strict patient and staff cohorting were introduced at both sites in August 2012. The outbreak was declared under control in September 2012. Extended infection control measures ended in May 2013. Patients on "high risk" wards, defined as those wards having extensive patient exchange with the ones where positive patients stayed, were screened for ESBL-KP once a week. Patients overlapping with positive patients on the ward were screened twice a week. Discharged patients who overlapped with positive patients between May and September 2012 were traced and retrospectively screened at home using a self-sampling kit. The kit contained two swabs used for the throat and rectum sampling. Instructions about how to use the kit were included. All patients were requested to send the kit back as soon as they took the samples. A case was defined as a patient infected or colonized with an ESBL-producing *K. pneumoniae* after 1^st^ May 2012 sharing the same antibiotic resistance pattern as the outbreak clone.

Screening and isolates collected in this study
----------------------------------------------

Screening of ESBL-producing Enterobacteriaceae (ESBL-E) was performed as described previously[@b10]. Briefly, patients were screened for ESBL-E carriage using perianal swabs (Eswab, Copan, Italy), and environmental screening was performed in the patient rooms (e.g. beds) and toilets (e.g. toilet chairs) using MW728 POLYWIPE® sponge swabs (Medical wire & equipment, Wiltshire, England). The swab was plated on a blood agar plate after vortexing, and the liquid Amies eluent was inoculated on selective tryptic soy broth with cefotaxime (0.25 mg/L) and vancomycin (8 mg/L) (TSB-VC). After 18--24 hours of incubation (35--37 °C), 10 μl TSB-VC was sub-cultured on both sides of an Extended Beta-Lactamase Screening Agar (EbSA) plate (AlphaOmega, 's-Gravenhage, Netherlands). The EbSA plate consists of a split MacConkey agar plate containing ceftazidime (1.0 mg/L) on one side and cefotaxime (1.0 mg/L) on the other side. Both sides contain cloxacillin (400 mg/L) and vancomycin (64 mg/L) for inhibition of AmpC beta-lactamase-producing bacteria and Gram-positive bacteria, respectively. Subsequently the plates were incubated aerobically at 35 to 37 °C for 18 to 24 hours. Species identification was performed for all oxidase negative isolates that grew on either side of the agar by MALDI-TOF (Bruker Daltonik GmbH, Bremen, Germany). In total, 19 *K. pneumoniae* isolates obtained from patients (KP-1 to KP12, KP-45D, KP-33P, KP-86L, and KP-33F) and environment (KP-1E to KP-3E) were included in this study. The details of isolates are listed in [Table 1](#t1){ref-type="table"}.

Conventional testing
--------------------

Phenotypic susceptibility testing was performed using the Vitek II system with card AST N-199 (BioMerieux, Marcy l′Etoile, France) according to the guidelines of the manufacturer. Breakpoints were interpreted according to EUCAST guidelines (bacteria v4.0). MLST was performed according to the protocol described on the *K. pneumoniae* MLST website ([www.pasteur.fr/mlst](http://www.pasteur.fr/mlst)). The sequence type (ST) was assigned by the MLST database ([www.pasteur.fr/mlst/Kpneumoniae.html](http://www.pasteur.fr/mlst/Kpneumoniae.html)).

WGS, de novo assembly and annotation
------------------------------------

A total of 19 isolates were sequenced. WGS and *de novo* assembly was performed as described previously[@b11]. Isolate KP-5 was randomly selected for being scaffolded by mate-pair sequencing. The mate-pair DNA library was prepared using the Mate Pair Library Prep Kit v2 (Illumina) according to the manufacturer's instructions followed by running on the Miseq for generating 100-bp reads. Scaffolding was performed by SSPACE standard version 3.0 with default settings[@b12]. Further gaps within scaffolds were attempted to be closed using GapFiller with default settings[@b13]. The genomes were manually curated after performing automatic annotation on the RAST server[@b14].

Identification of antibiotic resistance-related genes and virulence factors
---------------------------------------------------------------------------

Three types of drug-resistance genes were investigated, including acquired drug-resistance genes, genes of efflux pumps, and genes associated with drug resistance by specific mutations. Virulence factors studied here include adhesins, capsule production, iron uptake systems, nitrogen source utilization and secretion systems[@b15][@b16]. The acquired antimicrobial resistance genes were identified by uploading assembled genomes to the Resfinder server v2.1 (<http://cge.cbs.dtu.dk/services/ResFinder-2.1/>). The other genes relating to resistance and virulence were detected by using the mapping unit of CLC Genomics Workbench to map and/or by blasting assembled genomes to a pseudomolecule generated by concatenating a set of target genes. The capsular genotype was determined *in silico* by *wzi* typing[@b17]. Scaffolds with resistance-related and virulence genes were blasted against GenBank to identify their genetic location.

Detection of single-nucleotide polymorphisms (SNPs)
---------------------------------------------------

The scaffolded genome of isolate KP-5 was ordered and oriented relative to the finished genome *K. pneumoniae* PMK1 (Accession number: CP008929) via ABACAS[@b18]. Reads of other isolates were mapped to the rearranged KP-5 genome by CLC Genomics Workbench with default settings. Candidate SNPs were detected by the algorithm "Quality-based variant detection" of CLC Genomics Workbench. SNPs were filtered out as described previously to acquire high-quality core-genome SNPs[@b9].

Core-genome phylogenetic analysis
---------------------------------

Fragments (≥500 bp) shared by all genomes were collected and then concatenated resulting in a pseudomolecule defined as the core genome. The detected high-quality SNPs from outbreak isolates were used for SNP-based phylogenetic reconstruction by RAxML v7.4.2[@b19] with 1000 bootstrap replications under the general time-reversible model with Gamma correction (GTR+G). Assembled genomes and genomes retrieved from GenBank were aligned by ProgressiveMauve[@b20]. The alignment of core genomes was used for estimating the maximum likelihood (ML) phylogeny by RAxML v7.4.2 as mentioned above.

Identification of DNA signatures and development of outbreak-specific multiplex PCR
-----------------------------------------------------------------------------------

The core genome of outbreak isolates was blasted against our local *K. pneumoniae* genome database (76 genomes with diverse sequence types). The unique fragments were extracted and blasted against GenBank (update to 20 October 2014). The non-match fragments not related to mobile genetic elements (e.g. phages, plasmids, and transposons) were considered as the DNA signatures for the outbreak clone. Primers for multiplex PCR specific to DNA signatures were designed by MPprimer[@b21]. All PCR-positive isolates were confirmed and further characterized by WGS.

Results
=======

Outbreak description and intervention
-------------------------------------

The suspected index patient (patient 1) had been admitted to a hospital in Gambia for necrotizing pancreatitis before arriving to the Netherlands and was referred from a regional acute care hospital to the UMCG in May 2012. As an MRSA-screening test was negative before the patient arrived at the UMCG patient 1 was not placed in isolation upon admission. Subsequently, the patient was screened for ESBL-producing Enterobacteriaceae and tested positive for ESBL-KP. The patient therefore was immediately put into contact isolation which implied that medical staff was required to wear a gown and gloves when having contact with the patient. A second patient (patient 2) stayed three days at the same ward with patient 1 and was later found positive for an ESBL-KP during the ICU stay. Two further patients were identified (patient 3 and 4) staying on the same ICU as patient 2. The isolates obtained from these patients had identical antibiotic resistance features as those of patient 1 and 2. This triggered an investigation consisting of patient tracking, contact tracing and screening. Subsequently, another five patients (patient 5 to 9) sharing the same ward and facilities with patient 3 at the rehabilitation centre were found to be positive for ESBL-KP. [Supplementary Fig. S1](#S1){ref-type="supplementary-material"} illustrates the intra-hospital patient transfer. In November 2012, an ESBL-KP was isolated from another patient (patient 10) staying at the same ward as patients 3 and 8 who were treated in contact isolation.

In May 2013, a patient (patient 11) admitted to the neurological ICU at the UMCG was found to carry an ESBL-KP phenotypically indistinguishable from the 2012 outbreak strain on admission screening. Based on the genomic similarity between the isolate of patient 11 and the 2012 outbreak isolates, we were able to predict the grade of epidemiological relatedness (see below). Patient 11 had no contact with any of the ten positive patients. Other patients at the neurological ICU were repeatedly screened and tested negative. Patient 11 was transferred from a secondary hospital in a city about 80-kilometer south of the UMCG. Further investigation revealed that patient 11 resided in the room where patient 6, still positive for ESBL-KP, had stayed after referral from the rehabilitation centre to the secondary acute care hospital. In fact, a small outbreak with 4 patients was reported but isolates were not available for this investigation.

In September 2013, a patient (patient 12) admitted at the UMCG was identified to carry an ESBL-KP highly similar to the 2012 outbreak isolates using a clone-specific PCR (see below). No positive patients were found at the hospital during that time. Epidemiological investigation revealed that before this admission patient 12 resided in a room in November 2012 where patient 1 stayed two months before.

In total, twelve patients positive for a phylogenetically highly related strain (see below) were identified by screening more than 120 patients from May 2012 until September 2013. Seven of them developed a clinical infection ([Table 1](#t1){ref-type="table"}). [Figure 1](#f1){ref-type="fig"} shows the most likely transmission route between the patients.

Antimicrobial susceptibility and MLST typing
--------------------------------------------

The 12 isolates (KPO-1 to KPO-12) from the 12 positive patients shared identical antibiotic resistance patterns. They were ESBL positive and resistant to amoxicillin, amoxicillin-clavulanic-acid, cefuroxime, cefotaxime, ceftazidime, gentamicin, tobramycin, co-trimoxazole, ciprofloxacin, cefepime, norfloxacin, and trimethoprim.

The MLST typing results showed that all isolates were assigned to ST15 (MLST profile: 1-1-1-1-1-1-1), which is known as the major member of the epidemic clonal group (CG) 15[@b3].

Population genomic analysis
---------------------------

Phylogenetic analysis of the core genome carried out for isolates from patients (1--4) early during the course of the investigation revealed their isogenicity. Additional isolates from patients (5--10) identified through contact tracing and screening as well as isolate KP-11 from sporadic patient 11 in 2013 all fell into the same genetic cluster ([Fig. 2](#f2){ref-type="fig"}). The 11 isolates differed by only 7 SNPs in inter- and intragenic regions across the core genome (see [Supplementary Table S1](#S1){ref-type="supplementary-material"}). Indeed, three isolates obtained from patients at the UMCG (KP-1, KP-2 and KP-4) and another two from patients of the rehabilitation centre (KP-6 and KP-7) were identical, i.e. they had no SNPs in the core genome. This phylogeny is concordant with available epidemiological data. We also predicted that the 2013 isolate KP-11 was derived from the outbreak clone, and differed by 2-4 SNPs from available 2012 outbreak isolates ([Fig. 2](#f2){ref-type="fig"}).

To assess the population diversity of *K. pneumoniae* ST15, four non-outbreak ESBL-KP isolates obtained before and after the outbreak period at the UMCG ([Table 1](#t1){ref-type="table"}), and 10 strains retrieved from GenBank (see [Supplementary Table S2](#S1){ref-type="supplementary-material"} online) were included in the phylogenetic analysis. The ST15 strains were split into two distinct clades (I and II). Five ST15 strains (MGH63, MGH65, MGH75, BAMC07-18 and BIDMC-33B) isolated in US clustered with the outbreak clone (clade I) ([Fig. 2](#f2){ref-type="fig"}). A non-outbreak ST15 strain KP-33P isolated from a patient at the UMCG in 2010 was separated from the outbreak clone, but clustered tightly with an ST15 NDM-1-producing isolate PMK1 (82 SNPs) (clade II) causing a nosocomial outbreak in Nepal 2012[@b22].Another non-outbreak ST437 isolate KP-86L clustered with isolates of ST11 and ST258, belonging to the epidemic clone group 258.

Patient screening by an outbreak-specific multiplex PCR
-------------------------------------------------------

Three DNA signatures specific to the outbreak clone were identified. Two of them consisted of coding sequences for a hypothetical protein. The other one was located within the capsule biosynthesis region, which consisted of a glycosyltransferase-encoding gene. Primers for multiplex PCR were designed based on these three signatures (see [Supplementary Table S3](#S1){ref-type="supplementary-material"} online). To assess the discriminatory capability of the primers, we tested 35 isolates representing at least 20 different STs including ST15 (one isolate). The result showed that only the outbreak isolates were positive in the multiplex PCR, and that non-outbreak ST15 isolates can be successfully discriminated from the outbreak isolates (see [Supplementary Fig. S2](#S1){ref-type="supplementary-material"}).

In September 2013, an isolate KP-12 sharing an identical antibiogram with the outbreak clone was obtained from patient 12 ([Table 1](#t1){ref-type="table"}), and was identified to belong to the outbreak clone as the outbreak-specific PCR was positive. In March 2015, the outbreak-specific PCR was applied to exclude the genetic relation of three isolates obtained from 3 patients staying at the same ward, and having a similar antibiogram as the outbreak isolates. Results obtained using the outbreak-specific PCR were confirmed by WGS.

Environment screening
---------------------

In total, 10 of 57 environmental samples were tested positive for ESBL-KP. To assess the genetic relatedness between environmental and patient isolates, three environmental isolates (KP-E1, KP-E2, and KP-E3) were selected for WGS ([Table 1](#t1){ref-type="table"}). The phylogenetic analysis showed that all three isolates clustered with the patient isolates ([Fig. 2](#f2){ref-type="fig"}). Isolate KP-E2 (rehabilitation centre; 2012) was indistinguishable from those of five patients (KP-1, KP-2, KP-4, KP-6 and KP-7), and KP-E1 (rehabilitation centre; 2012) and KP-E3 (university hospital; 2013) differed by only up to 3 SNPs from all other patient isolates (see [Supplementary Table S1](#S1){ref-type="supplementary-material"} online).

Resistome
---------

Coding sequences associated with resistance were identified to elucidate the drug-resistance mechanisms of outbreak-associated isolates. [Table 2](#t2){ref-type="table"} shows those genes detected in the outbreak isolates. All outbreak isolates shared the same resistome. The ESBL gene *bla*~CTX-M-15~ and the non-ESBL gene *bla*~SHV-28~ were detected on the plasmid and chromosome, respectively. The detection of acquired drug-resistance genes allowed us to explain the phenotypical resistance profile. Further analyses identified non-synonymous SNPs in *acrR* (A165T) and *ramR* (G56A), resulting in an amino-acid substitution in AcrR (K55N) and RamR (A19V). These proteins are regulators of AcrAB-TolC and mutations in these regulators may cause overexpression of AcrAB resulting in MDR phenotypes[@b23]. Analysis of three well-described mutational hotspots associated with resistance to quinolone/fluoroquinolone showed non-synonymous nucleotide changes in *gyrA* and *parC* genes, resulting in amino-acid substitutions in DNA gyrase (S83F, D87A) and topoisomerase IV (S80I)[@b24].

Virulence factors
-----------------

All outbreak isolates shared the same virulence factors. [Table 3](#t3){ref-type="table"} shows the virulence factors identified in the outbreak clone, which were highly similar with those identified in the ST15 clade II isolate PMK1 from Nepal. Two hypervirulence-related iron uptake systems (ABC transporter Kfu and *Yersinia* high-pathogenicity island)[@b25], were found in the outbreak clone and PMK1 but not in the non-outbreak isolate KP-33P (clade II). Although both the outbreak clone and PMK1 harboured a genomic island carrying the *Yersinia* high-pathogenicity island (encoding yersiniabactin) and a type IV(A) secretion system, the island's compositions and its insertion site were rather different (see [Supplementary Fig. S3](#S1){ref-type="supplementary-material"}). The BLASTn result suggests that the genomic island of the outbreak clone may have been acquired from an *Escherichia coli* stain ED 1a ([Table 3](#t3){ref-type="table"}). As the other ST15 clade I isolates, the capsular genotype of the outbreak clone was *wzi*24, associated with serotype K24 (<http://bigsdb.web.pasteur.fr/klebsiella/klebsiella.html>). This was different from that of clade II isolates PMK1 and KP-33P, which was *wzi*93, associated with serotype K60 ([Fig. 3](#f3){ref-type="fig"}).

Discussion
==========

Controlling the dissemination of multidrug-resistant pathogens remains one of the major public health challenges in the 21^st^ century. Here, we share our experience in managing a regional outbreak caused by a HiRiC of ESBL-positive *K. pneumoniae* ST15. This lineage has previously been implicated in hospital outbreaks worldwide[@b4][@b22][@b26][@b27]. The regional and temporal dimension of this outbreak was initially unexpected but became visible when WGS data were compared with a locally available database. The outbreak involved patients from three institutions in two cities within an 80-km distance located in the same province of the Netherlands and may well have gone beyond the reach of our regional infection control capacity. The high infection rate of the outbreak clone in patients and the rebound of two patients a year after the start of the outbreak are indicators for the virulence and tenacity of this clone fulfilling the criteria of a HiRiC[@b28][@b29][@b30].

The strength of WGS can be fully appreciated when considering that no obvious epidemiological association existed between a sporadic patient in 2013 (patient 11) and patients belonging to a transmission cluster one year before. A compelling degree of sequence homology consisting of 2--4 SNPs difference in the core genome between isolates from unrelated patients, led us to suggest a link, which was subsequently vindicated by epidemiological investigation. The results showed that high-resolution epidemiological typing could support infection control initiatives in unambiguously clustering patients colonized or infected with bacterial species otherwise abundant in clinical specimen.

We demonstrated that tailor-made diagnostic markers by identifying genomic signatures could highly improve the efficiency of infection control, especially for HiRiCs that may be perpetuated in health care networks. Indeed, the outbreak-specific PCR allowed us to rapidly and undoubtedly identify another "sporadic" patient (patient 12) more than one year after the start of the outbreak. Most importantly, this method enables to distinguish outbreak isolates from non-outbreak isolates even if they shared the same sequence type (i.e. ST15 isolate KP-33P). These advantages facilitate the early detection of patients, which can be greatly helpful for the prevention of clonal spread and patient treatments.

The higher resolution of WGS is also an advantage on global-scale epidemiological typing comparing to conventional methods (e.g. MLST). This greatly helps us to dissect the population structure of opportunistic bacterial pathogens by identifying HiRiCs, i.e. clonal lineages of particular public health importance. Recent work based on WGS analysis reveals that *K. pneumoniae* ST258, another HiRiC associated with the global dissemination KPC carbapenemase, is actually composed of two distinct genetic clades, which challenges conventional hypotheses on clonal descent[@b31]. Similarly, our study shows that the population structure of ST15 may be diverse, as two clades were formed by the ST15 isolates analysed. Full understanding of the ST15 genomic population structure will be helpful for the infection management of this HiRiC. Notably, the non-outbreak ST15 isolate KP-33P obtained in 2010 in the UMCG clustered with a ST15 NDM-1-producing Nepali outbreak isolate PMK1 (82 SNPs), suggesting that they share a common ancestor.

Noteworthy, ST15 clades I and II carried two different capsular serotypes (K24 and K60), respectively. This is similar as the recent finding that ST258 clades I and II were mainly differentiated by an \~215-kb region including *cps* genes[@b31]. Capsular serotypes are known to be associated with different virulence-associated traits (e.g. immune evasion and biofilm formation) in carbapenem-resistant *K. pneumoniae*[@b32]. The role of the different capsular serotypes in the pathogenicity of ST15 should be studied in the future to allow improved risk-assessment (i.e. identify hypervirulence- and/or epidemic-related capsule serotypes) and novel therapy (i.e. use of anti-capsule antibodies). Additionally, a *Yersinia* high-pathogenicity island encoding yersiniabactin was identified in the outbreak clone. This factor was also present in the Nepali outbreak isolate PMK1, but not in the non-outbreak ST15 isolate KP-33P. A recent study showed that yersiniabactin is essential for *K. pneumoniae* to become an effective respiratory pathogen[@b33]. This may be one of reasons for the high infection rate (\~58.3%) observed during the outbreak and further suggests that the capacity to rapidly acquire virulence factors is important to become a HiRiC.

Analysis of the resistome identified a set of plasmid-borne resistance genes (*bla*~CTX-M-15~-*bla*~TEM-1~-*bla*~OXA-1~-*aac(6*′*)-Ib-cr*-*qnrB*1) in the outbreak clone that was found in *Enterbacteriaceae* populations spreading throughout Europe[@b34][@b35][@b36][@b37][@b38]. Acquisition of such resistome may confer an advantage to HiRiCs, thereby stimulating their emergence. Indeed, a highly similar resistome was identified in a new *K. pneumoniae* clone (ST1427) causing a nosocomial outbreak in our hospital[@b39]. Therefore, active surveillance of epidemic plasmid with certain resistome will be helpful in preventing HiRiCs dissemination.

Our study can be useful for making appropriate intervention/prevention strategies for HiRiCs in the future. First of all, the capacity to contaminate the environment facilitates the dissemination of the outbreak clone. Therefore, complete decontaminations, including cleaning and disinfection of surfaces likely to be contaminated by patients (e.g. bed and toilets) are extremely important for outbreak prevention and control. Secondly, frequent screening of patients, especially those receiving long-term healthcare and/or extensive antibiotic treatment, is required for controlling and preventing transmissions. Furthermore, extensive collaboration on diagnostics and infection prevention within a healthcare network[@b40], is important for efficient infection prevention and control. For this, a shared database containing information on characteristics of circulating clones and data of intra- as well as inter-hospital patient transfer would be of great help.

In summary, our study highlights challenges in managing the outbreak of *K. pneumoniae* HiRiCs, suggesting the necessity of frequent surveillance and inter-institutional collaborations for infection/outbreak prevention and control.
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![Putative transmission route of the regional outbreak.\
The transmission route was reconstructed by epidemiological and genomic data (see Appendix Materials and Methods for details of reconstruction methods). Each node represents a patient, and an arrow indicates a possible transmission event from one patient to another. The blue arrow with solid line represents a direct transmission event supported by both epidemiological data and genetic data, the blue arrow with dash line represents an indirect transmission (e.g. via environment) supported by epidemiological data, and the red arrow indicates the equally parsimonious transmission link which cannot be resolved by neither epidemiological data nor genetic data. The inter-institutional transfer of the patient is shown by dash line, on which the distance between institutions is indicated. The red star represents an outbreak at the secondary hospital, but the isolates were unavailable for our investigation.](srep20840-f1){#f1}

![Core-genome phylogenetic analysis of *K. pneumoniae* isolates.\
A maximum likelihood tree was constructed based on the alignments of a 4.47 Mb genome, defined as the core genome in this study. The tree was mid-point rooted. The size of node represents the percentage of bootstrap support, and the biggest one is equal to 100. Sequence types are indicated between brackets. The isolation time and resource of all ST15 strains are shown. The cluster of outbreak isolates is simplified as a red triangle. The non-outbreak isolates sequenced in this study are in blue, and the others retrieved from GenBank are in black. The inset shows the close-up unrooted tree of outbreak isolates, in which the patient isolates are shown in red (2012) and purple (2013), and the environment isolates are in green. The number of SNPs is indicated on the branches.](srep20840-f2){#f2}

![Comparison of capsular polysaccharide synthesis (*cps*) region identified from ST15 isolates.\
The *cps* regions of *K. pneumoniae* PMK1 and KP-33P (non-outbreak isolate of this study) were identical. The *cps* region of a ST15 strain was retrieved from GenBank. The gradients (dark to pale) of the alignment region represent the percentage of sequence identity between samples defined by BLASTn.](srep20840-f3){#f3}

###### Patients and *K. pneumoniae* isolates involved in this study.

  Patient ID[\*](#t1-fn1){ref-type="fn"}          Location                        Infection site                 Sample Date   Sample ID    ST
  ---------------------------------------- ----------------------- -------------------------------------------- ------------- ----------- -------
  1                                          University hospital     Colonization[†](#t1-fn3){ref-type="fn"}     30/05/2012      KP-1      ST15
  2                                          University hospital    Multiple sites[\#](#t1-fn2){ref-type="fn"}   03/06/2012      KP-2      ST15
  3                                         Rehabilitation center            Lower respiratory tract             26/06/2012      KP-3      ST15
  4                                          University hospital    Multiple sites[\#](#t1-fn2){ref-type="fn"}   01/07/2012      KP-4      ST15
  5                                         Rehabilitation center                  Urine tract                   16/07/2012      KP-5      ST15
  6                                         Rehabilitation center                  Urine tract                   14/08/2012      KP-6      ST15
  7                                         Rehabilitation center                  Urine tract                   30/08/2012      KP-7      ST15
  8                                         Rehabilitation center    Colonization[†](#t1-fn3){ref-type="fn"}     03/09/2012      KP-8      ST15
  9                                         Rehabilitation center    Colonization[†](#t1-fn3){ref-type="fn"}     13/09/2012      KP-9      ST15
  10                                        Rehabilitation center    Colonization[†](#t1-fn3){ref-type="fn"}     24/11/2012      KP-10     ST15
  11                                         University hospital             Lower respiratory tract             02/05/2013      KP-11     ST15
  12                                         University hospital     Colonization[†](#t1-fn3){ref-type="fn"}     03/09/2013      KP-12     ST15
  Unrelated                                  University hospital     Colonization[†](#t1-fn3){ref-type="fn"}     27/01/2012     KP-45D     ST163
  Unrelated                                  University hospital                      Blood                      12/08/2010     KP-33P     ST15
  Unrelated                                  University hospital                      Blood                      23/11/2012     KP-86L     ST437
  Unrelated                                  University hospital                      Blood                      01/08/2013     KP-33F     ST307
  Environment                               Rehabilitation center                      Bed                       10/09/2012      KP-1E     ST15
  Environment                               Rehabilitation center                  Toilet chair                  10/09/2012      KP-2E     ST15
  Environment                                University hospital                   Toilet chair                  29/10/2013      KP-3E     ST15

^\*^All isolates shared an identical antibiogram. They were ESBL positive and resistant to amoxicillin, amoxicillin-clavulanic-acid, cefuroxime, cefotaxime, ceftazidime, gentamicin, tobramycin, co-trimoxazole, ciprofloxacin, cefepime, norfloxacin, and trimethoprim and susceptible to imipenem, polymyxin B, cefoxitin and meropenem.

^\#^Multiple infection sites include blood, urine tract, lower respiratory tract, and central venous line.

^†^Colonization was defined by positive cultures acquired from throat and/or rectum samples.

###### Coding sequences related to drug resistance present in the outbreak clone.

  Category                                          Genetic context                          Resistance phenotype                                                
  ----------------------------------------------- ------------------- ------------------------------------------------------------------ ------------------------------------------------
  Drug-resistance gene                                                                                                                    Best Hit[\*](#t2-fn1){ref-type="fn"}(Identity)
  *bla*~TEM-1~                                          Plasmid        Penicillins, narrow-spectrum cephalosporins, inhibitor-sensitive                  100% (JF910132)
  *bla*~OXA-1~                                          Plasmid                        Penicillins, inhibitor-resistant                                   100% (J02967)
  *bla*~SHV-28~                                       Chromosome       Penicillins, narrow-spectrum cephalosporins, inhibitor-sensitive                  100% (AF538324)
  *bla*~CTX-M-15~                                       Plasmid            Penicillins, extended-spectrum cephalosporins, aztreonam                      100% (DQ302097)
  *strAB*                                               Plasmid                                  Streptomycin                                        100% (AF321551, M96392)
  *aac(6')-Ib-cr*                                       Plasmid                       Aminoglycosides, fluoroquinolones                                  100% (DQ303918)
  *aac(3)-II*                                           Plasmid                 Gentamicin, tobramycin, netilmicin, sisomicin                            100% (JX424423)
  *qnrB1*                                               Plasmid                          Quinolones, fluoroquinolones                                   100% (NG_036203.1)
  *sul2*                                                Plasmid                                  Sulfonamides                                            100% (GQ421466)
  *dfrA14*                                              Plasmid                                  Trimethoprim                                            100% (GU726917)
  *fosA*                                              Chromosome                                  Fosfomycin                                              99% (CP009114)
  *tetA*(A)                                             Plasmid                                 Tetracyclines                                            100% (AJ517790)
  Efflux pump (familiy)                                                                                                                  
  *acrAB-tolC* (RND)[†](#t2-fn2){ref-type="fn"}       Chromosome            Aminoglycosides, beta-lactams, tigecycline, macrolides                         PMK1 (100%)
  *acrD* (RND)                                        Chromosome           Aminoglycosides, deoxycholate, fusidic acid, novobiocin                         PMK1 (100%)
  *mdtABC* (RND)                                      Chromosome                     Deoxycholate, novobiocin, bile salt                                   PMK1 (100%)
  *oqxAB* (RND)                                       Chromosome               Chloramphenicol, fluoroquinolones, trimethoprim                         99%/100% (CP009461)
  *bcr* (MF)                                          Chromosome                         Bicyclomycin, sulfathiazole                                       PMK1 (100%)
  *emrAB* (MF)                                        Chromosome                    Nalidixic acid, hydrophobic compounds                                  PMK1 (100%)
  *fsr* (MF)                                          Chromosome                                 Fosmidomycin                                              PMK1 (100%)
  *mdfA* (*kdeA*) (MF)                                Chromosome              Aminoglycosides, fluoroquinolones, chloramphenicol                           PMK1 (100%)
  *mdtG* (MF)                                         Chromosome                           Deoxycholate, fosfomycin                                        PMK1 (100%)
  *mdtH* (MF)                                         Chromosome                            Enoxacin, norfloxacin                                          PMK1 (100%)
  *mdtL* (MF)                                         Chromosome                               Chloramphenicol                                             PMK1 (100%)
  *smvA*(MF)                                          Chromosome                  Acriflavine, quaternary ammonium compounds                               PMK1 (100%)
  *sugE* (SMR)                                        Chromosome                   Benzalkonium chloride, ethidium bromide                                 PMK1 (100%)
  *mdtK* (MATE)                                       Chromosome                           Acriflavine, norfloxacin                                        PMK1 (100%)
  *macAB-tolC* (ABC)                                  Chromosome                                  Macrolides                                               PMK1 (100%)
  Gene with point mutation                         Amino-acid change                                                                                             
  *gyrA*                                              S83F, D87A                         Quinolones, fluoroquinolones                                            
  *parC*                                                 S80I                            Quinolones, fluoroquinolones                                            

^\*^The best hit is defined by Blastn on <http://blast.ncbi.nlm.nih.gov/Blast.cgi>. All matches are *K. pneumoniae* with 100% coverages.

^†^There was a nonsynonymous SNP causing an amino-acid substitution (K55N) in AcrR.

###### Coding sequences related to virulence factors present in the outbreak clone.

  Virulence factor                                                            Gene(s) detected                            Best hit[\*](#t3-fn1){ref-type="fn"}(coverage, identity)   Genetic context
  -------------------------------------------------- ------------------------------------------------------------------- ---------------------------------------------------------- -----------------
  Adhesin                                                                                                                                                                           
  Type 1 fimbriae                                                              *fimBEAICDFGHK*                                                PMK1 (100%, 99%)                         Chromosome
  Type 3 fimbriae                                                                *mrkABCDF*                                                  PMK1 (100%, 100%)                         Chromosome
  Kpa fimbriae                                                                   *kpaABCDE*                                                  PMK1 (100%, 100%)                         Chromosome
  Kpb-like fimbriae^±^                                                         *kpbRABCD*~*2*~                                               PMK1 (100%, 100%)                         Chromosome
  Kpe fimbriae[\#](#t3-fn3){ref-type="fn"}                                     *ΔkpeA, kpeBCD*                                               PMK1 (100%, 100%)                         Chromosome
  Kpf fimbriae                                                                   *kpfRABCD*                                                  PMK1 (100%, 100%)                         Chromosome
  Kpg fimbriae                                                                    *kpgABCD*                                                pittNDM01 (100%, 99%)                       Chromosome
  Fim2[ǂ](#t3-fn4){ref-type="fn"}                                   *fim2AIC*, *fim2D*::*tnpA*, *fimF-K*                                     PMK1 (100%, 100%)                         Chromosome
  ECP (Mat) fimbriae                                                             *ecpRABCDE*                                                 PMK1 (100%, 100%)                         Chromosome
  polysaccharide adhesin                                                          *pgaABCD*                                                  PMK1 (100%, 100%)                         Chromosome
  Capsule                                                                                                                                                                           
  *wzi*24/K24                                              *galF-wzc, wcaJ-ugd*^†^ ([Fig. 3](#f3){ref-type="fig"})                      ATCC 43816 KPPR1 (50%, 95%)                    Chromosome
  Iron uptake system                                                                                                                                                                
  Fep-ent (Enterobactin)                                     *fepA-entD, fes-entF, fepDGC, ybdA, fepB, entCEBA*                              PMK1 (100%, 100%)                         Chromosome
  Iuc (Aerobactin)                                                                 *iutA*                                                    PMK1 (100%, 100%)                         Chromosome
  IroA (Salmochelin)                                                               *iroN*                                                    PMK1 (100%, 100%)                         Chromosome
  Fhu (Ferrichrome)                                                               *fhuACDB*                                                  PMK1 (100%, 100%)                         Chromosome
  ABC transporter Sit (Ferrous iron)                                              *sitABCD*                                                  PMK1 (100%, 100%)                         Chromosome
  ABC transporter Eit (Iron/B12/siderophore/hemin)                                *eitABCD*                                                  PMK1 (100%, 100%)                         Chromosome
  ABC transporter Kfu (Ferric iron)                                               *kfuABC*                                                   PMK1 (100%, 100%)                         Chromosome
  High-pathogenicity island (Yersiniabactin)                        *ybtPQXS, ybtA-irp2-irp1-ybtUTE-fyuA*                               *E. coli* ED 1a (100%, 99%)                    Chromosome
  Feo (Ferrous iron)                                                              *feoABC*                                                   PMK1 (100%, 100%)                         Chromosome
  Hmu (Hemin/hemoprotein)                                                        *hmuRSTUV*                                                  PMK1 (100%, 100%)                         Chromosome
  Nitrogen source utilization                                                                                                                                                       
  Urease                                                                        *ureDCBAEFG*                                                 PMK1 (100%, 100%)                         Chromosome
  Secretion system                                                                                                                                                                  
  F-type T4SS                                                *traALEKBVCGFHNUW, trbC*[†](#t3-fn4){ref-type="fn"}                        JM45 plasmid p1 (100%, 99%)                      Plasmid
  T4SS (type IVA)                                                 *virB1-2*, *virB4-6*, *virB8-11*, *virD4*                             *E. coli* ED 1a (100%, 99%)                    Chromosome
  T6SS                                                *impH-G, imcF, vgrG, ompA, impJ, clpV*[†](#t3-fn4){ref-type="fn"}                      PMK1 (100%, 100%)                         Chromosome

^\*^The best hit is defined by Blastn on <http://blast.ncbi.nlm.nih.gov/Blast.cgi>. The species name is not shown if the matches are from *K. pneumoniae*. ^±^The adhesin gene *kpbD* was replaced by a different adhesin gene *kpdD*~*2*~ (the gene was named in this study).

^\#^The subunit gene *kpeA* was replaced by a gene encoding Tn903 transposase.

^ǂ^The intact gene cluster of this fimbriae was identified on a genomic island KpGI-5 (JN181158) of *K. pneumoniae* KR116.

^†^Only conserved/hallmark genes are shown here.

[^1]: These authors contributed equally to this work.
